In June 2025, major pharmaceutical companies executed high-profile transactions and collaborations to expand their drug discovery capabilities. Sanofi acquired Blueprint Medicines for $9.1 billion, enhancing its portfolio in rare immunological diseases and oncology with innovative kinase inhibitors. Novo Nordisk partnered with Deep Apple Therapeutics to develop small molecule obesity drugs, while Bristol Myers Squibb (BMS) invested $350 million upfront in Philochem’s radiolabeled ligand targeting ACP3, and initiated collaboration with BioNTech on PD-L1xVEGF-A bispecific antibodies. Gilead Sciences also teamed up with Kymera to pursue oral molecular glue degraders targeting CDK2. These moves reflect an intensifying push among pharma giants into novel modalities and diverse therapeutic areas, leveraging in-house and partnered innovation to strengthen pipelines and maintain competitive advantage.